• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Glycotope (Group)

Glycotope (www.glycotope.com), founded in 2001 in Berlin, focuses on the development of innovative immune-oncological products for the treatment of various cancer types using their GlycoBody™ and GlycoExpress™ technologies. Glycotope´s GEX™ platform allows glyco-optimization of a variety of fully human glycosylated biopharmaceuticals such as coagulation factors, cytokines, glycoprotein hormones, antibodies, and other protein based biopharmaceuticals by using a toolbox of glyco-engineered proprietary human cell lines that allow for optimization of a whole series of different determining sugars. In addition, the GEX™ platform offers high yield production with unmet quality and reproducibility. Glycotope’s entire human blood coagulation business was recently partnered with Octapharma in an exclusive strategic deal in October 2015. *

 

	Start	2001-01-01 established
	Industry	GlycoExpress™ cellular expression system (GEX™ technology)
	Industry 2	glycomics
	Person	Kollenberg, Henner (Glycotope 201403– Managing Director (CFO) + Eckert Life Science Acclerator before Qonsult Group)
	Person 2	Bracht, Franzpeter (Celonic 201711– COO before Glycotope + Aplagen + Ernst & Young + Kienbaum)
	Region	Berlin
	Country	Germany
	Street	10 Robert-Rössle-Str.
	City	13125 Berlin
	Tel	+49-30-9489-2604
		Address record changed: 2018-07-24
Basic data	Employees	D: 101 to 500 (2016-01-07)
		* Document for �About Section�: Glycotope GmbH. (1/7/16). "Press Release: Glycotope Names Paul G Higham as New Chief Executive Officer". Berlin.
		Record changed: 2020-01-01

Advertisement

More documents for Glycotope (Group)

• [1] Glycotope GmbH. (7/18/18). "Press Release: DCPrime and Glycotope Announce Licensing Agreement and Collaboration". Leiden & Berlin....
• [2] Glycotope GmbH. (10/30/17). "Press Release: Daiichi Sankyo and Glycotope Announce Option Agreement for Antibody Drug Conjugate Strategic Collaboration and Licensing". Tokyo, Basking Ridge, NJ & Berlin....
• [3] Glycotope GmbH. (4/29/16). "Press Release: Glycotope Appoints Dr. Alfredo Zurlo as Chief Medical Officer". Berlin....
• [4] Glycotope GmbH. (1/7/16). "Press Release: Glycotope Names Paul G Higham as New Chief Executive Officer". Berlin....
• [5] Glycotope GmbH. (10/8/15). "Press Release: Glycotope and Octapharma Enter Exclusive Worldwide License Agreement on Human Blood Coagulation Factors". Berlin & Lachen....
• [6] Glycotope GmbH. (3/20/14). "Press Release: Glycotope Names Henner Kollenberg as Managing Director and Chief Financial Officer". Berlin....
• [7] Glycotope GmbH. (3/11/14). "Press Release: Glycotope Secures One of the Largest Financing Rounds in the European Biotech Sector". Berlin....
• [8] Glycotope GmbH. (10/16/13). "Press Release: Glycotope Reported Promising First-in-Man Data of Novel Glycooptimized Monoclonal Anti-TA-MUC1 Antibody PankoMab-GEX". Berlin....
• [9] Glycotope GmbH. (9/27/13). "Press Release: Glycotope Presents Phase I Results of Novel Glycooptimized Monoclonal anti-TA-MUC1 Antibody PankoMAb-GEX at European Cancer Congress". Berlin....
• [10] Glycotope GmbH. (9/19/11). "Press Release: Glycotope Enrolls First Patients in Phase I Trial with TrasGEX, a Glycooptimized HER2 Biobetter Antibody". Berlin....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2020. Made in Germany.